Table 1.

Demographics and surgical outcomes according to preoperative BMI

Preoperative BMI (kg/m2)
<18.518.5 to <23.023.0 to <25.025.0 to <27.5≥27.5Total
Characteristic(n = 82)(n = 761)(n = 539)(n = 456)(n = 225)(n = 2,063)
Age, year60.8 ± 16.260.2 ± 13.160.4 ± 12.059.9 ± 11.359.5 ± 12.360.1 ± 12.5
Sex, n (%)
 Male55 (67.1)485 (63.7)385 (71.4)340 (74.6)143 (63.6)1,408 (68.3)
 Female27 (32.9)276 (36.3)154 (28.6)116 (25.4)82 (36.4)655 (31.7)
ASA classification
 I44 (53.7)389 (51.1)269 (49.9)198 (43.4)81 (36.0)981 (47.6)
 II35 (42.7)331 (43.5)247 (45.8)245 (53.7)134 (59.6)992 (48.1)
 ≥III3 (3.7)41 (5.4)23 (4.3)13 (2.9)10 (4.4)90 (4.4)
Smoking status, n (%)
 Never44 (53.7)468 (61.5)308 (57.1)267 (58.6)138 (61.3)1,225 (59.4)
 Past16 (19.5)132 (17.3)103 (19.1)70 (15.4)33 (14.7)354 (17.2)
 Current22 (26.8)161 (21.2)128 (23.7)119 (26.1)54 (24.0)484 (23.5)
Postoperative BMI (kg/m2), n (%)
 <18.550 (74.6)147 (22.4)9 (1.8)2 (0.5)0208 (11.3)
 18.5 to <23.017 (25.4)493 (75.3)372 (76.2)179 (41.7)20 (9.7)1,081 (58.6)
 23.0 to <25.0013 (2.0)99 (20.3)173 (40.3)79 (38.3)364 (19.7)
 25.0 to <27.502 (0.3)8 (1.6)73 (17.0)62 (30.1)145 (7.9)
 ≥27.50002 (0.5)45 (21.8)47 (2.5)
BMI loss (kg/m2)−0.3 ± 1.71.5 ± 1.52.2 ± 1.52.8 ± 1.83.8 ± 1.92.2 ± 1.9
Extent of resection, n (%)
 Distal gastrectomy65 (79.3)567 (74.5)432 (80.1)363 (79.6)176 (78.2)1,603 (77.7)
 Total gastrectomy13 (15.9)146 (19.2)80 (14.8)65 (14.3)30 (13.3)334 (16.2)
 Proximal gastrectomy4 (4.9)39 (5.1)23 (4.3)22 (4.8)17 (7.6)105 (5.1)
 Pylorus-preserving gastrectomy09 (1.2)4 (0.7)6 (1.3)2 (0.9)21 (1.0)
No. of retrieved lymph nodes54.2 ± 22.751.6 ± 19.652.8 ± 20.051.4 ± 20.353.8 ± 24.452.2 ± 20.6
Extent of lymphadenectomy, n (%)
 D1+30 (36.6)354 (46.5)273 (50.6)225 (49.3)111 (49.3)993 (48.1)
 ≥D252 (63.4)407 (53.5)266 (49.4)231 (50.7)114 (50.7)1,070 (51.9)
 Operation time, minutes164.3 ± 51.3170.9 ± 58.9179.0 ± 58.2178.4 ± 56.7183.5 ± 56.4175.8 ± 57.8
Estimated blood loss, mL136.9 ± 146.3126.5 ± 109.4135.1 ± 116.0138.5 ± 123.6138.3 ± 142.3133.1 ± 119.8
Tumor size, cm4.3 ± 2.83.8 ± 2.63.4 ± 2.13.4 ± 2.33.3 ± 2.23.6 ± 2.4
Histologic type, n (%)
 Differentiated58 (70.7)532 (69.9)393 (72.9)336 (73.7)153 (68.0)1472 (71.4)
 Undifferentiated20 (24.4)209 (27.5)130 (24.1)103 (22.6)60 (26.7)522 (25.3)
 Others4 (4.9)20 (2.6)16 (3.0)17 (3.7)12 (5.3)69 (3.3)
pT-stage, n (%)
 T145 (54.9)460 (60.4)349 (64.7)297 (65.1)158 (70.2)1,309 (63.5)
 ≥T237 (45.1)301 (39.6)190 (35.3)159 (34.9)67 (29.8)754 (36.5)
pN-stage, n (%)
 N048 (58.5)495 (65.0)364 (67.5)314 (68.9)162 (72.0)1383 (67.0)
 ≥N134 (41.5)266 (35.0)175 (32.5)142 (31.1)63 (28.0)680 (33.0)
pStagea, n (%)
 I47 (57.3)489 (64.3)373 (69.2)311 (68.2)165 (73.3)1385 (67.1)
 II11 (13.4)119 (15.6)82 (15.2)71 (15.6)30 (13.3)313 (15.2)
 III24 (29.3)153 (20.1)84 (15.6)74 (16.2)30 (13.3)365 (17.7)
Adjuvant chemotherapy, n (%)
 No65 (79.3)584 (76.7)414 (76.8)347 (76.1)179 (79.6)1589 (77.0)
 Yes17 (20.7)177 (23.3)125 (23.2)109 (23.9)46 (20.4)474 (23.0)
  • Abbreviation: p, pathologic.

  • aThe TNM stage was determined according to the seventh edition of the American Joint Committee on Cancer staging manual.21